Table II.

Study Participant Demographics and Clinical Characteristics

	Agea/Raceb/Sexc	Site of involvementd	Immunosuppression	Ag85Ae	2	3	6	9
Sarcoidosis 1	34CF	P	None	< 50	135	300	290	440
Sarcoidosis 2	41CF	P, C	None	330
Sarcoidosis 3	47CF	P	Steroids	< 50	150	160	160
Sarcoidosis 4	56CF	P	None	66
Sarcoidosis 5	55CF	P	Steroids	86
Sarcoidosis 6	64CF	P	None	120	0	0	0	0
Sarcoidosis 7	55AAF	P	None	150	50	0	70	0
Sarcoidosis 8	48CF	P	None	< 50	0	115	0	0
Sarcoidosis 9	51AAF	C	Steroids	< 50
Sarcoidosis 10	42CM	P	None	160
Sarcoidosis 11	49AAF	P, CNS	Steroids	130	75	90	95	0
Sarcoidosis 12	51AAF	P	Steroids, pentoxifylline	110
Sarcoidosis 13	31AAM	P, C, CNS	Steroids	275
Sarcoidosis 14	53CF	P, C	Steroids	60
Sarcoidosis 15	61CF	P	Pentoxifylline	50
Sarcoidosis 16	37CM	P	None	120	0	0	0	0
Sarcoidosis 17	45AAF	P	None	200		75	60
Sarcoidosis 18	45CM	P, C	None	120	0	0	0	0
Sarcoidosis 19	22AAF	C	Steroids	180	0	0	0	125
Sarcoidosis 20	43AAF	P	None	< 50	0	0	0	0
Sarcoidosis 21	56CM	P	Steroids	< 50	0	0	0	0
Sarcoidosis 22	49CF	P	None	< 50
Sarcoidosis 23	54CF	P	Humera	< 50
Sarcoidosis 24	63CM	P	None	< 50	0	0	0	0
Sarcoidosis 25	34CM	P	Steroids	< 50	0	0	0	0
Control 1	23CM	None	None	120
Control 2	27AAF	None	None	200		0	0	50
Control 3	32AAF	None	None	< 50	0	0	0	0
Control 4	24CF	None	None	< 50
Control 5	37CF	None	None	< 50
Control 6	25CF	None	None	< 50
Control 7	31AAM	None	None	< 50
Control 8	52CF	None	None	< 50
Control 9	35CF	None	None	< 50	0	0	0	0
Control 10	53CF	None	None	< 50
Control 11	58CF	None	None	< 50	0	0	0	70
Control 12	34AAF	None	None	< 50
Control 13	31CM	None	None	< 50
Control 14	43AAF	None	None	< 50	0	0	0	0
Control 15	57CF	None	None	< 50	0	0	0	0
Control 16	32CF	None	None	< 50	0	0	0	0
Control 17	55AAF	None	None	< 50	0	0	0	0
Control 18	35AAM	None	None	< 50	0	0	0	0
Control 19	32AAF	None	None	< 50	0	0	0	0
Control 20	42AAF	None	None	< 50	0	0	0	0
Control 21	27AAF	None	None	< 50
Control 22	33AAF	None	None	< 50
PPD+ 1	34CF	Latent	None	75	240	0	0	140
PPD+ 2	41AAF	Latent	None	200	0	0	0	0
PPD+ 3	45CF	Latent	None	605	0	75	0	0
PPD+ 4	50CF	Latent	None	475	0	0	0	0
PPD+ 5	38CF	Latent	None	< 50	0	0	0	0
PPD+ 6	63CF	Latent	None	500	0	0	0	0
PPD+ 7	58AAF	Latent	None	50	0	75	0	0
PPD+ 8	30CM	Latent	None	110	0	0	0	75
PPD+ 9	57AAM	Latent	None	1400
PPD+ 10	49CF	Latent	None	285	0	0	0	0
PPD+ 11	64CF	Latent	None	190	0	0	0	0
PPD+ 12	47CF	Latent	None	172
PPD+ 13	46CF	Latent	None	212
PPD+ 14	60AAF	Latent	None	70	0	0	0	0
PPD+ 15	49CF	Latent	None	630		0	0
PPD+ 16	49CF	Latent	None	< 50	0	0	0	0

^aAge in years.

^bAA, African-American; C, Caucasian.

^cF, female, M, male.

^dP, Pulmonary; C, Cutaneous, CNS; Central nervous system.

^eInteferon-γ producing spot-forming cells per million PBMC.